Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

ANI Pharma Inc (NQ: ANIP )

49.81 +0.55 (+1.12%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 30, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 208,773
Open 49.48
Bid (Size) 48.83 (1)
Ask (Size) 67.05 (1)
Prev. Close 49.26
Today's Range 49.25 - 50.38
52wk Range 36.36 - 65.89
Shares Outstanding 24,422,240
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Why Is Generic Drug Player ANI Pharmaceuticals Stock Trading Lower Today?
ANI Pharmaceuticals Inc's (NASDAQ: ANIP) third-quarter revenues were $131.8 million, up 57.3% Y/Y, beating the  
Via Benzinga
Expert Ratings for ANI Pharmaceuticals
Via Benzinga

Performance

YTD
+24.40%
+24.40%
1 Month
-17.67%
-17.67%
3 Month
-22.91%
-22.91%
6 Month
+10.35%
+10.35%
1 Year
+22.50%
+22.50%

More News

Read More
Analyst Expectations for ANI Pharmaceuticals's Future
Via Benzinga
ANI Pharmaceuticals Inc. (NASDAQ: ANIP) Records 52-Week High Wednesday Morning
Via Investor Brand Network
What 4 Analyst Ratings Have To Say About ANI Pharmaceuticals
Via Benzinga
7 A-Rated Biotech Stocks for Your August Buy List
Via InvestorPlace
Where ANI Pharmaceuticals Stands With Analysts
Via Benzinga
Looking Into ANI Pharmaceuticals's Return On Capital Employed
Via Benzinga
Why ANI Pharmaceuticals Stock Is Soaring Today
Via Benzinga
Earnings Preview For ANI Pharmaceuticals
Via Benzinga
ANI Pharmaceuticals to Present at the Jefferies Healthcare Conference
From ANI Pharmaceuticals, Inc.
Via Business Wire
ANI Pharmaceuticals Announces Closing of Public Offering of Common Stock Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
From ANI Pharmaceuticals, Inc.
Via Business Wire
ANI Pharmaceuticals Announces FDA Approval and Commercialization of Two ANDAs with CGT Exclusivity
From ANI Pharmaceuticals, Inc.
Via Business Wire
ANI Pharmaceuticals Announces Pricing of $75 Million Public Offering of Common Stock
From ANI Pharmaceuticals, Inc.
Via Business Wire
ANI Pharmaceuticals Earnings Perspective: Return On Capital Employed
Via Benzinga
ANI Pharmaceuticals Announces Proposed Public Offering of Common Stock
From ANI Pharmaceuticals, Inc.
Via Business Wire
Stocks Reverse Gains Ahead Of Slew Of Inflation Data
Via Talk Markets
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
ANI Pharmaceuticals Reports Record First Quarter 2023 Financial Results and Raises Full-Year 2023 Guidance
From ANI Pharmaceuticals, Inc.
Via Business Wire
Why Tredegar Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
ANI Pharmaceuticals to Discuss First Quarter 2023 Financial Results on May 8, 2023, at 8:30 a.m. ET
From ANI Pharmaceuticals, Inc.
Via Business Wire
ANI Pharmaceuticals to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ
From ANI Pharmaceuticals, Inc.
Via Business Wire
ANI Pharmaceuticals Announces the FDA Approval and Launch of Nitrofurantoin Oral Suspension USP
From ANI Pharmaceuticals, Inc.
Via Business Wire
ANI Pharmaceuticals Announces the FDA Approval of Colestipol Hydrochloride Tablets USP
From ANI Pharmaceuticals, Inc.
Via Business Wire
ANI Pharmaceuticals Reports Record Fourth Quarter Financial Results and Achieves Full Year 2022 Revenue Milestone; Initiates 2023 Guidance
From ANI Pharmaceuticals, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.